

Translational Research, Design and Analysis Perspective

Cite this article: Sege RD and Laraque-Arena D. Steps towards equity in research. *Journal of Clinical and Translational Science* 7: e65, 1–3. doi: [10.1017/cts.2023.8](https://doi.org/10.1017/cts.2023.8)

Received: 3 December 2022

Accepted: 17 January 2023

Address for correspondence:

R. D. Sege, MD, PhD, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Box 063, 800 Washington Street, Boston, MA 02111, USA.
Email: rsege@tuftsmedicalcenter.org

Robert D. Sege and Danielle Laraque-Arena are co-first authors.

© The Author(s), 2023. Published by Cambridge University Press on behalf of The Association for Clinical and Translational Science. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.



Steps towards equity in research

Robert D. Sege¹  and Danielle Laraque-Arena^{2,3}

¹Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; ²New York Academy of Medicine, New York, NY, USA and ³Mailman School of Public Health and Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA

Steps towards Equity in Research

Health disparities in the United States of America (USA) contribute to relatively low and declining life expectancy as compared to other OECD countries [1–4]. We explore how clinical translational research can address health equity, beginning with an understanding of how research has failed to address racial disparities in health and concluding with feasible actions to redress research practices.

What Research Is Done?

Research concerning diseases that primarily affect marginalized US populations are underfunded and understudied. Farooq reported that research funding related to sickle cell disease (SSD), the most common monogenic disease in the USA, amounts to under \$1000/affected person, while cystic fibrosis (CF) funding (the most common monogenic disease among White Americans) is over \$10,000/person. Research investment matters: individuals with CF have new treatments and near-normal life expectancy, while advances in treatment for SSD and life expectancy have lagged [5].

Examples of inequitable funding abound: research on triple-negative breast cancer, common among African American women, is relatively underfunded. At least 200,000 US adults, primarily Black and Latina women, have Systemic Lupus Erythematosus; however, in 2021 NIH set aside less than \$900/affected person. Firearms injuries, the leading cause of death in children and adolescents [6,7], disproportionately affect young Black men, but until recently federal law effectively prohibited public health studies to reduce firearms injuries.

Who Does the Research and How Is It Funded?

Underrepresentation of Black scientists may underlie the problems in studying issues relevant to Black Americans. Black investigators account for only about 2% of NIH-funded Principal Investigators.

Felicia Marie Knaul, economist and researcher of global health and breast cancer, points to research funding fueled by distinct personal interest and siloed fundraising resulting in missed opportunities to address systemic issues [8].

Hoppe noted 3 problem areas that lead to disparate peer-review outcomes: decision to discuss, impact score assignment, and topic choice [9]. Black applicants chose topics such as community and population health that receive lower award rates than investigator-initiated proposals at earlier translational stages. Study sections, drawn from the ranks of funded investigator, may have less enthusiasm for research focused on minoritized communities or relevance to public health or health disparities.

Research Participation

Clinical research involves the participation of affected individuals. Black Americans are far less likely to enroll in research trials than would be expected based on disease prevalence [10]. Although better framing of randomized controlled trials and medical professional training may help [11,12], the distrust of research may be well justified. Recent papers have suggested that Black and White research participants are treated differently within the same trials [13].

Results Reporting

Knowledge of health disparities depends on data availability. A recent analysis demonstrated that only 38% of published articles describing clinical trials for cancer drug approvals indicated the proportion of research participants who were Black [10]. Research reports should expand the use of the ten-year-old PRISMA Equity guidelines [14] or the recent International Journal editors' recommendations [15].

A Pathway to Equity through Translational Research Redesign

Clinical translational science can diversify research teams, match research priorities with health needs, improve diverse research participation, and follow guidelines for results reporting.

This perspective echoes a recent NAM Perspective plan of action for dismantling racism in the research endeavor [16]. The recommendations are anchored on the principle of addressing leading causes of death throughout the life course and the training of medical professionals in socially accountable, competency-based educational models [6,7,17,18]. The lack of diversity in the entire research workforce can be addressed through programs that improve access to careers as independent investigators and engage community residents as co-researchers [19].

Addressing the Urgent Need for Change

What NIH Can Do?

Effective efforts towards diversity of the educational pipeline will have delayed effects because the median age of new NIH R01 investigators is 44 years old. However, as suggested by Selker, the clinical translational science can make concerted efforts now to include individuals from marginalized communities in research as part of broadly engaged research teams [20]. This broadly engaged team science model offers a paradigm shift that can be instituted in clinical translational science.

We also propose a multi-pronged approach that includes needed competencies that support understanding the burden of disease for diverse US and global populations, adopting community accountability approaches that advance equity in research [17], and hiring diverse scholars and research staff.

Within the clinical translational science training programs, we can ensure that our trainees graduate equipped with tools to identify, understand, and address issues related to health disparities. These tools extend standard training in biostatistics, epidemiology, and ethics with skills related to social epidemiology, use of qualitative and quantitative measures, exposure to metrics of inequality, critical tools for evaluating data sources, and experience in reporting research results in standard recommended formats that promote equity [14,15]. In our personal experience, trainees are very interested in this emerging field of study.

Lastly, building trust between the research community and the public requires a change in mindset among investigators to include issues of health equity in their work, improvements in science communication, and the creation of meaningful community advisory boards for clinical translational science institutes. The enormous investment in biomedical and translational research has accelerated the health impact of the recent explosion in scientific knowledge. Attention to health disparities can help translate these advances to improvements in health and longevity.

Acknowledgements. The authors would like to thank Quinn Tucker for her assistance in preparing this perspective. RDS was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Disclosures. The authors state that they have no conflicts of interest to disclose.

References

1. Arias E, Tajeda-Vera B, Kochanek K, Ahmad F. *National Vital Statistics Rapid Release: Provisional Life Expectancy Estimated for 2021. National Vital Statistics System*, 2022. (www.cdc.gov/nchs/data/vsrr/vsrr023.pdf).
2. Woolf SH, Aron L. Failing health of the United States. *BMJ* 2018; **360**: k496. DOI: [10.1136/bmj.k496](https://doi.org/10.1136/bmj.k496).
3. Avendano M, Kawachi I. Why do Americans have shorter life expectancy and worse health than do people in other high-income countries? *Annual Rev Public Health* 2014; **35**(1): 307–325. DOI: [10.1146/annurev-publhealth-032013-182411](https://doi.org/10.1146/annurev-publhealth-032013-182411).
4. GBD US Health Disparities Collaborators. Life expectancy by county, race, and ethnicity in the USA, 2000–19: A systematic analysis of health disparities. *Lancet* 2022; **400**(10345): 25–38. DOI: [10.1016/S0140-6736\(22\)00876-5](https://doi.org/10.1016/S0140-6736(22)00876-5).
5. Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. *JAMA Network Open* 2020; **3**(3): e201737. DOI: [10.1001/jamanetworkopen.2020.1737](https://doi.org/10.1001/jamanetworkopen.2020.1737).
6. Goldstick JE, Cunningham RM, Carter PM. Current causes of death in children and adolescents in the United States. *New England Journal of Medicine* 2022; **386**(20): 1955–1956. DOI: [10.1056/nejmc2201761](https://doi.org/10.1056/nejmc2201761).
7. Lee LK, Douglas K, Hemenway D. Crossing lines — a change in the leading cause of death among U.S. children. *New England Journal of Medicine* 2022; **386**(16): 1485–1487. DOI: [10.1056/nejmp2200169](https://doi.org/10.1056/nejmp2200169).
8. International Conference on the Future of Health Profession Education. University of Miami, Miami, FL, November 2–4, 2022. (<https://web.cvent.com/event/969ebfc1-f835-4279-a949-eb104e445b9/summary>).
9. Hoppe TA, Litovitz A, Willis KA, et al. Topic choice contributes to the lower rate of NIH Awards to African-American/black scientists. *Science Advances* 2019; **5**(10). DOI: [10.1126/sciadv.aaw7238](https://doi.org/10.1126/sciadv.aaw7238).
10. Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. *JAMA Oncology* 2019; **5**(10): e191870. DOI: [10.1001/jamaoncol.2019.1870](https://doi.org/10.1001/jamaoncol.2019.1870).
11. Jull J, Whitehead M, Petticrew M, et al. When is a randomised controlled trial health equity relevant? development and validation of a conceptual framework. *BMJ Open* 2017; **7**(9): e015815. DOI: [10.1136/bmjopen-2016-015815](https://doi.org/10.1136/bmjopen-2016-015815).
12. Wanty NI, Cooper DL, Simkus A, et al. A provider-based approach to address racial disparities in lupus clinical trial participation. *Arthritis Care & Research* 2022. DOI: [10.1002/acr.25054](https://doi.org/10.1002/acr.25054).
13. Odugbesan O, Addala A, Nelson G, et al. Implicit racial-ethnic and insurance-mediated bias to recommending diabetes technology: Insights from T1D exchange multicenter pediatric and adult diabetes provider cohort. *Diabetes Technology & Therapeutics* 2022; **24**(9): 619–627. DOI: [10.1089/dia.2022.0042](https://doi.org/10.1089/dia.2022.0042).
14. Welch V, Petticrew M, Tugwell P, et al. Prisma-equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. *PLoS Medicine* 2012; **9**(10): e1001333. DOI: [10.1371/journal.pmed.1001333](https://doi.org/10.1371/journal.pmed.1001333).
15. Flanagan A, Frey T, Christiansen SL, AMA Manual of Style Committee. Updated guidance on the reporting of race and ethnicity in medical and science journals. *JAMA* 2021; **326**(7): 621–627.
16. Beard K, Iruka I, Laraque-Arena D, McBride Murry V, Rodriguez L, Taylor S. Dismantling systemic racism and advancing health equity throughout research. *NAM Perspectives* 2022; **1**. DOI: [10.31478/202201a](https://doi.org/10.31478/202201a).
17. Laraque-Arena D, Etzel RA. Tool 2: organizational change - helping from inside. In: Laraque-Arena D, Germain L, Young V, Laraque-Ho A, eds. *Leadership at the Intersection of Gender and Race in Healthcare and Science: Case Studies and Tools*. New York: Routledge; 2023. 191–220.

18. **Halfon N, Russ SA, Kahn RS.** Inequality and child health: dynamic population health interventions. *Current Opinion in Pediatrics* 2021; **34**(1): 33–38. DOI: [10.1097/mop.0000000000001087](https://doi.org/10.1097/mop.0000000000001087).
19. **Bogard K, Ortiz-Cortes V, Taylor S, Jackson R, Belmonte R.** An exploratory approach to defining and measuring child health and well-being with parents and grandparents. *Pediatric Medicine* 2021; **4**: 22. DOI: [10.21037/pm-20-110](https://doi.org/10.21037/pm-20-110).
20. **Selker HP, Wilkins CH.** From community engagement to community-engaged research, to broadly engaged team science. *Journal of Clinical and Translational Science* 2017; **1**(1): 5–6. DOI: [10.1017/cts.2017.1](https://doi.org/10.1017/cts.2017.1).